Shan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shan Liu has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
Yani Ke
School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
8 shared publicationsKaihan Wu
The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China
6 shared publicationsShuaihang Chen
The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China
6 shared publicationsYuqing Zhu
The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China
6 shared publicationsJie Hu
Department of Infectious The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine) Hangzhou Zhejiang China
5 shared publicationsChenglu Shen
The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China
4 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (2) , 102259
Impact of adding statins to non-selective beta-blockers in cirrhosis with portal hypertension: a systematic review and meta-analysis of randomized controlled trials
- 20 July 2026
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (2) , 102259
Open AccessImpact of adding statins to non-selective beta-blockers in cirrhosis with portal hypertension: a systematic review and meta-analysis of randomized controlled trials
- Open Access
- 16 March 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1) , 2635832
Cord blood transfusion added matched unrelated donor transplantation as a preferable choice for aplastic anaemia: a comparative study from a single centre
Aplastic anaemia (AA) is a bone marrow failure syndrome caused by aberrant immune responses and is associated with high mortality and poor prognosis, particularly in patients with severe aplastic a...
- 16 March 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1) , 2635832
Open AccessCord blood transfusion added matched unrelated donor transplantation as a preferable choice for aplastic anaemia: a comparative study from a single centre
Aplastic anaemia (AA) is a bone marrow failure syndrome caused by aberrant immune responses and is associated with high mortality and poor prognosis, particularly in patients with severe aplastic a...
- Open Access
Peripheral versus Marrow Lipidomics in Patients with Severe Aplastic Anemia: Potential Indicators for Early Immunosuppressive Treatment Response
This study aimed to explore the differences of peripheral blood ( PB ) and bone marrow serum lipidomic profiles in severe aplastic anemia ( SAA ) patients and their significance in predicting earlier immunosuppressive therapy ( IST ) response. A cohort of 11 newly diagnosed SAA patients and 15 healthy controls were enrolled between June 2020 and November 2022, and six of the SAA patients received ATG ‐based IST . PB and BM serum were collected for further LC – MS / MS analysis. Compared to donors, SAA patients exhibited more pronounced abnormalities in lipid metabolism profiles within BM serum relative to PB serum. Specifically, elevated levels of free fatty acids ( FA ), fatty acid esters of hydroxyl fatty acids ( FAHFA ), and phosphatidylserine ( PS ) were noted in the BM serum of SAA patients. Following treatment, there was a noted increase in acylcarnitine ( ACar ), hexosylceramide non‐hydroxy fatty acid‐sphingosine ( HexCer ‐ NS ), and sulfur hexosyl ceramide hydroxy fatty acid ( SHexCer ), while levels of lysophosphatidylcholine ( LPC ) and oxidized phosphatidylcholine ( OxPC ) diminished, particularly in complete or partial response ( CR / PR ) patients. Acknowledging the changes of BM lipidomics may contribute to earlier prediction of ATG ‐based IST response in SAA patients.
Open AccessPeripheral versus Marrow Lipidomics in Patients with Severe Aplastic Anemia: Potential Indicators for Early Immunosuppressive Treatment Response
This study aimed to explore the differences of peripheral blood ( PB ) and bone marrow serum lipidomic profiles in severe aplastic anemia ( SAA ) patients and their significance in predicting earlier immunosuppressive therapy ( IST ) response. A cohort of 11 newly diagnosed SAA patients and 15 healthy controls were enrolled between June 2020 and November 2022, and six of the SAA patients received ATG ‐based IST . PB and BM serum were collected for further LC – MS / MS analysis. Compared to donors, SAA patients exhibited more pronounced abnormalities in lipid metabolism profiles within BM serum relative to PB serum. Specifically, elevated levels of free fatty acids ( FA ), fatty acid esters of hydroxyl fatty acids ( FAHFA ), and phosphatidylserine ( PS ) were noted in the BM serum of SAA patients. Following treatment, there was a noted increase in acylcarnitine ( ACar ), hexosylceramide non‐hydroxy fatty acid‐sphingosine ( HexCer ‐ NS ), and sulfur hexosyl ceramide hydroxy fatty acid ( SHexCer ), while levels of lysophosphatidylcholine ( LPC ) and oxidized phosphatidylcholine ( OxPC ) diminished, particularly in complete or partial response ( CR / PR ) patients. Acknowledging the changes of BM lipidomics may contribute to earlier prediction of ATG ‐based IST response in SAA patients.
- Top Cited PapersOpen Access
- 2 January 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (1) , e2556012
Life-Course Psychosocial Stress and Risk of Dementia and Stroke in Middle-Aged and Older Adults
Importance: The associations of adverse childhood experiences (ACEs) and adverse adulthood experiences (AAEs) with incident dementia and stroke in the Chinese population are not well understood. Objectives: To investigate the associations of ACEs and AAEs with dementia and stroke incidence, and to examine whether depression mediates these associations. Design, Setting, and Participants: This population-based cohort study utilized data from the China Health and Retirement Longitudinal Study (June 2015 to December 2020). Participants aged 45 years and older with complete adverse experience data were included and were followed up for a mean (SD) of 4.89 (0.48) years for dementia and 4.84 (0.57) years for stroke. Statistical analysis was performed from August 20, 2025, to November 23, 2025. Exposures: ACEs and AAEs were assessed through a structured questionnaire, with cumulative scores calculated for both categories. Main Outcomes and Measures: Dementia was identified using a standardized cognitive battery and activities of daily living scale, while stroke was determined through self-reported physician diagnosis. Depression was evaluated using the 10-item Centre for Epidemiologic Studies Depression Scale. Cox proportional hazards regression analysis was used to explore the association of ACEs and AAEs with the risk of new-onset dementia and stroke, with results presented as hazard ratios (HRs) with 95% CIs. Results: Among 11 601 participants (mean [SD] age, 59.18 [9.41] years; 5569 male [48.0%]), 9145 (78.8%) were exposed to at least 1 ACE indicator, 4241 (36.6%) to at least 1 AAE indicator, and 3531 (30.4%) to both ACE and AAE markers. Both ACEs (HR, 1.11; 95% CI, 1.05-1.18) and AAEs (HR, 1.23; 95% CI, 1.14-1.33) were significantly associated with higher hazards of dementia during follow-up, whereas only AAEs were associated with higher hazards of stroke (HR, 1.19; 95% CI, 1.12-1.26). Latent class analysis identified a high-risk ACEs subgroup associated with incident stroke (HR, 1.33; 95% CI, 1.08-1.65). In the joint effects analyses, participants in the high-risk groups for both ACEs and AAEs exhibited higher hazards of dementia (HR, 3.28; 95% CI, 1.54-7.02) and stroke (HR, 2.50; 95% CI, 1.24-5.30). Depression mediated 34.3% of the association of ACEs with dementia (β = 0.10; 95% CI, 0.04-0.17), 20.9% of the association of AAEs with dementia (β = 0.22; 95% CI, 0.13-0.30), and 17.5% of the association of AAEs with stroke (β = 0.18; 95% CI, 0.11-0.24). Conclusions and Relevance: In this cohort study, exposure to adverse experiences throughout life was associated with increased risks of dementia and stroke, with depression mediating these associations. These findings highlight the importance of implementing life-course interventions that address both psychological trauma and mental health to reduce the burden of neurovascular diseases.
- 2 January 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (1) , e2556012
Top Cited PapersOpen AccessLife-Course Psychosocial Stress and Risk of Dementia and Stroke in Middle-Aged and Older Adults
Importance: The associations of adverse childhood experiences (ACEs) and adverse adulthood experiences (AAEs) with incident dementia and stroke in the Chinese population are not well understood. Objectives: To investigate the associations of ACEs and AAEs with dementia and stroke incidence, and to examine whether depression mediates these associations. Design, Setting, and Participants: This population-based cohort study utilized data from the China Health and Retirement Longitudinal Study (June 2015 to December 2020). Participants aged 45 years and older with complete adverse experience data were included and were followed up for a mean (SD) of 4.89 (0.48) years for dementia and 4.84 (0.57) years for stroke. Statistical analysis was performed from August 20, 2025, to November 23, 2025. Exposures: ACEs and AAEs were assessed through a structured questionnaire, with cumulative scores calculated for both categories. Main Outcomes and Measures: Dementia was identified using a standardized cognitive battery and activities of daily living scale, while stroke was determined through self-reported physician diagnosis. Depression was evaluated using the 10-item Centre for Epidemiologic Studies Depression Scale. Cox proportional hazards regression analysis was used to explore the association of ACEs and AAEs with the risk of new-onset dementia and stroke, with results presented as hazard ratios (HRs) with 95% CIs. Results: Among 11 601 participants (mean [SD] age, 59.18 [9.41] years; 5569 male [48.0%]), 9145 (78.8%) were exposed to at least 1 ACE indicator, 4241 (36.6%) to at least 1 AAE indicator, and 3531 (30.4%) to both ACE and AAE markers. Both ACEs (HR, 1.11; 95% CI, 1.05-1.18) and AAEs (HR, 1.23; 95% CI, 1.14-1.33) were significantly associated with higher hazards of dementia during follow-up, whereas only AAEs were associated with higher hazards of stroke (HR, 1.19; 95% CI, 1.12-1.26). Latent class analysis identified a high-risk ACEs subgroup associated with incident stroke (HR, 1.33; 95% CI, 1.08-1.65). In the joint effects analyses, participants in the high-risk groups for both ACEs and AAEs exhibited higher hazards of dementia (HR, 3.28; 95% CI, 1.54-7.02) and stroke (HR, 2.50; 95% CI, 1.24-5.30). Depression mediated 34.3% of the association of ACEs with dementia (β = 0.10; 95% CI, 0.04-0.17), 20.9% of the association of AAEs with dementia (β = 0.22; 95% CI, 0.13-0.30), and 17.5% of the association of AAEs with stroke (β = 0.18; 95% CI, 0.11-0.24). Conclusions and Relevance: In this cohort study, exposure to adverse experiences throughout life was associated with increased risks of dementia and stroke, with depression mediating these associations. These findings highlight the importance of implementing life-course interventions that address both psychological trauma and mental health to reduce the burden of neurovascular diseases.
- Open Access
- 1 January 2026
- Published by Wiley in Indoor Air
- Vol. 2026 (1)
Impact of Volatile Organic Compound Mixtures on Cardiovascular Health in Adults With Metabolic Dysfunction–Associated Fatty Liver Disease: A US Population Study
Background: Metabolic dysfunction–associated fatty liver disease (MAFLD) is among the most prevalent chronic liver diseases worldwide, whereas cardiovascular disease remains the primary cause of mortality in this population. Volatile organic compounds (VOCs), ubiquitous in the environment, have been linked to adverse cardiovascular outcomes; however, their impact on cardiovascular health (CVH) in MAFLD remains underexplored. Methods: We performed an analysis of nationally representative National Health and Nutrition Examination Survey (NHANES) data from 2011 to 2020. Urinary 15 VOC metabolites were obtained from laboratory measurements using standardized ultraperformance liquid chromatography–electrospray tandem mass spectrometry. CVH was assessed using the Life′s Essential 8 (LE8) and Life′s Crucial 9 (LC9). Mixed‐exposure effects and individual contributions were examined using survey‐weighted linear regression, weighted quantile sum (WQS), quantile g‐computation (q‐gcomp), and Bayesian kernel machine regression (BKMR). Results: Among 1280 adults with MAFLD, higher VOCs exposure was associated with lower CVH (LE8: β = −5.51, p < 0.001; LC9: β = −4.90, p < 0.001), WQS (LE8: β = −2.30, p < 0.001; LC9: β = −2.05, p < 0.001) and q‐gcomp (LE8: β = −1.09, p = 0.04; LC9: β = −0.97, p = 0.04) supported inverse mixture associations, whereas BKMR showed pronounced decrements at higher mixture percentiles among nicotine‐exposed participants (75th percentile LE8: β = −6.18, p < 0.001; LC9: β = −4.90, p < 0.001). Across methods, the metabolites CYMA (acrylonitrile), MHBMA3 (1,3‐butadiene), and HPMMA (crotonaldehyde) emerged as the dominant contributors. Conclusion: In US adults with MAFLD, mixed VOCs exposure was consistently linked to poorer CVH and had a stronger association in those with nicotine exposure.
- 1 January 2026
- Published by Wiley in Indoor Air
- Vol. 2026 (1)
Open AccessImpact of Volatile Organic Compound Mixtures on Cardiovascular Health in Adults With Metabolic Dysfunction–Associated Fatty Liver Disease: A US Population Study
Background: Metabolic dysfunction–associated fatty liver disease (MAFLD) is among the most prevalent chronic liver diseases worldwide, whereas cardiovascular disease remains the primary cause of mortality in this population. Volatile organic compounds (VOCs), ubiquitous in the environment, have been linked to adverse cardiovascular outcomes; however, their impact on cardiovascular health (CVH) in MAFLD remains underexplored. Methods: We performed an analysis of nationally representative National Health and Nutrition Examination Survey (NHANES) data from 2011 to 2020. Urinary 15 VOC metabolites were obtained from laboratory measurements using standardized ultraperformance liquid chromatography–electrospray tandem mass spectrometry. CVH was assessed using the Life′s Essential 8 (LE8) and Life′s Crucial 9 (LC9). Mixed‐exposure effects and individual contributions were examined using survey‐weighted linear regression, weighted quantile sum (WQS), quantile g‐computation (q‐gcomp), and Bayesian kernel machine regression (BKMR). Results: Among 1280 adults with MAFLD, higher VOCs exposure was associated with lower CVH (LE8: β = −5.51, p < 0.001; LC9: β = −4.90, p < 0.001), WQS (LE8: β = −2.30, p < 0.001; LC9: β = −2.05, p < 0.001) and q‐gcomp (LE8: β = −1.09, p = 0.04; LC9: β = −0.97, p = 0.04) supported inverse mixture associations, whereas BKMR showed pronounced decrements at higher mixture percentiles among nicotine‐exposed participants (75th percentile LE8: β = −6.18, p < 0.001; LC9: β = −4.90, p < 0.001). Across methods, the metabolites CYMA (acrylonitrile), MHBMA3 (1,3‐butadiene), and HPMMA (crotonaldehyde) emerged as the dominant contributors. Conclusion: In US adults with MAFLD, mixed VOCs exposure was consistently linked to poorer CVH and had a stronger association in those with nicotine exposure.
- 4 December 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (3) , 1603-1613
Non‐invasive diagnosis of metabolic dysfunction‐associated steatotic liver disease: Current status, challenges, and future directions
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most prevalent liver disease globally and a significant public health challenge posing serious threats to human health. Although a liver biopsy is considered the gold standard for diagnosing MASLD, its invasiveness, high cost, and associated risks limit its clinical applicability. With the rapid advancements in artificial intelligence and imaging technologies, non‐invasive biomarkers and machine learning techniques are increasingly being used in the diagnosis of MASLD. This article systematically reviews the latest developments in non‐invasive diagnostic technologies for MASLD, focusing on four major areas: serological, imaging, multi‐omics, and AI‐driven diagnostic models. This study aims to provide evidence‐based insights for precise clinical diagnosis, ultimately facilitating early warning, dynamic monitoring, and individualized management of MASLD.
- 4 December 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (3) , 1603-1613
Non‐invasive diagnosis of metabolic dysfunction‐associated steatotic liver disease: Current status, challenges, and future directions
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most prevalent liver disease globally and a significant public health challenge posing serious threats to human health. Although a liver biopsy is considered the gold standard for diagnosing MASLD, its invasiveness, high cost, and associated risks limit its clinical applicability. With the rapid advancements in artificial intelligence and imaging technologies, non‐invasive biomarkers and machine learning techniques are increasingly being used in the diagnosis of MASLD. This article systematically reviews the latest developments in non‐invasive diagnostic technologies for MASLD, focusing on four major areas: serological, imaging, multi‐omics, and AI‐driven diagnostic models. This study aims to provide evidence‐based insights for precise clinical diagnosis, ultimately facilitating early warning, dynamic monitoring, and individualized management of MASLD.
- Open Access
- 6 November 2025
- Published by Elsevier in Clinical Traditional Medicine and Pharmacology
- Vol. 6 (4)
The clinical advantage of pan-colonic enema with Compound Qingdai on the remission of extensive ulcerative colitis
- 6 November 2025
- Published by Elsevier in Clinical Traditional Medicine and Pharmacology
- Vol. 6 (4)
Open AccessThe clinical advantage of pan-colonic enema with Compound Qingdai on the remission of extensive ulcerative colitis
- Open Access
- 20 August 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-13
An updated systematic review and meta-analysis: correlation between circulating plasminogen activator inhibitor-1 levels and metabolic dysfunction-associated steatotic liver disease
Background Metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly known as non-alcoholic fatty liver disease—is the leading cause of chronic liver disease globally. However, early diagnosis and specific treatment have not yet been achieved. Plasminogen activator inhibitor-1 (PAI-1) is closely related to MASLD and may be an important indicator for its diagnosis and treatment. This updated meta-analysis aimed to comprehensively explore the relationship between circulating PAI-1 levels and MASLD. Methods Article retrieval was carried out in seven provenances (PubMed, Cochrane Library, EMBASE, CNKI, WANFANG, Clinical Trials Database, and Grey Literature Database) using free text words and MeSH terms. The meta-analysis was performed using RevMan 5.3 and Stata 12. Outcomes were presented as standardised mean difference (SMD) with 95% confidence intervals (CI). Results A total of 23 studies were included in the meta-analysis. The levels of circulating PAI-1 in patients with MASLD were significantly higher than those in healthy controls (SMD = 1.44, 95% CI [1.06, 1.83]). Subgroup and meta-regression analyses based on key factors, such as area, age, and BMI, were performed to explore the sources of heterogeneity. In the BMI subgroup analysis, the participants were divided into two groups. While the subgroup results were inconclusive, the meta-regression suggested that the area (i.e. the geographic region of the study population) may be a major contributor to heterogeneity (p < 0.001). Conclusions Patients with MASLD have significantly high circulating PAI-1 levels; however, this correlation may vary in different regions, thereby providing a reference for further research on MASLD.
- 20 August 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-13
Open AccessAn updated systematic review and meta-analysis: correlation between circulating plasminogen activator inhibitor-1 levels and metabolic dysfunction-associated steatotic liver disease
Background Metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly known as non-alcoholic fatty liver disease—is the leading cause of chronic liver disease globally. However, early diagnosis and specific treatment have not yet been achieved. Plasminogen activator inhibitor-1 (PAI-1) is closely related to MASLD and may be an important indicator for its diagnosis and treatment. This updated meta-analysis aimed to comprehensively explore the relationship between circulating PAI-1 levels and MASLD. Methods Article retrieval was carried out in seven provenances (PubMed, Cochrane Library, EMBASE, CNKI, WANFANG, Clinical Trials Database, and Grey Literature Database) using free text words and MeSH terms. The meta-analysis was performed using RevMan 5.3 and Stata 12. Outcomes were presented as standardised mean difference (SMD) with 95% confidence intervals (CI). Results A total of 23 studies were included in the meta-analysis. The levels of circulating PAI-1 in patients with MASLD were significantly higher than those in healthy controls (SMD = 1.44, 95% CI [1.06, 1.83]). Subgroup and meta-regression analyses based on key factors, such as area, age, and BMI, were performed to explore the sources of heterogeneity. In the BMI subgroup analysis, the participants were divided into two groups. While the subgroup results were inconclusive, the meta-regression suggested that the area (i.e. the geographic region of the study population) may be a major contributor to heterogeneity (p < 0.001). Conclusions Patients with MASLD have significantly high circulating PAI-1 levels; however, this correlation may vary in different regions, thereby providing a reference for further research on MASLD.
- Open Access
- 8 August 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (9) , 4859-4862
High complicated incidence of Gilbert’s syndrome in patients with thalassemia: deserve earlier identification and less oversight
- 8 August 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (9) , 4859-4862
Open AccessHigh complicated incidence of Gilbert’s syndrome in patients with thalassemia: deserve earlier identification and less oversight
- Open Access
- 18 July 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (29) , e43434
Non-surgical treatment of cyclosporin A-induced gingival overgrowth: A systematic review and meta-analysis
Background: Cyclosporin A-induced (CsA-induced) gingival overgrowth (GO) is a common side effect affecting many patients. While surgical intervention is often considered the primary treatment, the effectiveness of nonsurgical periodontal therapy for CsA-induced GO remains unclear. This meta-analysis aimed to assess the efficacy of nonsurgical periodontal treatment in CsA-induced GO. Methods: Articles were retrieved from 7 databases (Cochrane Library, PubMed, EMBASE, China National Knowledge Infrastructure, Chinese Academic Database, Clinical Trials Database, and Grey Literature Database) until November 5th, 2024. Randomized controlled trials (RCTs) or pre–post studies containing patients with GO caused by cyclosporine who received nonsurgical periodontal treatment were included. The protocol was published in International Prospective Register of Systematic Reviews with the ID CRD42024570280. Results: A total of 13 studies were included. Five studies were RCTs comparing nonsurgical periodontal treatment groups and control groups among patients with GO; the other 8 studies were single group pre–post studies. Meta-analysis of RCTs demonstrated the hypertrophy index (standardized mean difference [SMD] = −1.14; 95% confidence intervals [CI]: [−1.59, −0.69]) and plaque index (SMD = −1.06, 95% CI: [−2.04, −0.07]) were significantly lower in the nonsurgical treatment groups than those in the control groups. Meta-analysis of single group pre–post studies showed that the levels of hypertrophy index (SMD = −1.49; 95% CI: [−2.92, −0.06]), probing depth (SMD = −1.52, 95% CI: [−2.46, −0.58]) and plaque index (SMD = −1.53, 95% CI: [−2.18, −0.88]) decreased significantly after treatment. Subgroup analyses indicated that antibiotics are important sources of heterogeneity. Conclusion: This meta-analysis supports the effectiveness of nonsurgical treatments for CsA-induced GO, and comprehensive pre and posttransplant oral care is recommended. Further studies are needed to determine the biological mechanisms and influence of each variable on the efficacy of nonsurgical treatments in reducing drug-induced GO.
- 18 July 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (29) , e43434
Open AccessNon-surgical treatment of cyclosporin A-induced gingival overgrowth: A systematic review and meta-analysis
Background: Cyclosporin A-induced (CsA-induced) gingival overgrowth (GO) is a common side effect affecting many patients. While surgical intervention is often considered the primary treatment, the effectiveness of nonsurgical periodontal therapy for CsA-induced GO remains unclear. This meta-analysis aimed to assess the efficacy of nonsurgical periodontal treatment in CsA-induced GO. Methods: Articles were retrieved from 7 databases (Cochrane Library, PubMed, EMBASE, China National Knowledge Infrastructure, Chinese Academic Database, Clinical Trials Database, and Grey Literature Database) until November 5th, 2024. Randomized controlled trials (RCTs) or pre–post studies containing patients with GO caused by cyclosporine who received nonsurgical periodontal treatment were included. The protocol was published in International Prospective Register of Systematic Reviews with the ID CRD42024570280. Results: A total of 13 studies were included. Five studies were RCTs comparing nonsurgical periodontal treatment groups and control groups among patients with GO; the other 8 studies were single group pre–post studies. Meta-analysis of RCTs demonstrated the hypertrophy index (standardized mean difference [SMD] = −1.14; 95% confidence intervals [CI]: [−1.59, −0.69]) and plaque index (SMD = −1.06, 95% CI: [−2.04, −0.07]) were significantly lower in the nonsurgical treatment groups than those in the control groups. Meta-analysis of single group pre–post studies showed that the levels of hypertrophy index (SMD = −1.49; 95% CI: [−2.92, −0.06]), probing depth (SMD = −1.52, 95% CI: [−2.46, −0.58]) and plaque index (SMD = −1.53, 95% CI: [−2.18, −0.88]) decreased significantly after treatment. Subgroup analyses indicated that antibiotics are important sources of heterogeneity. Conclusion: This meta-analysis supports the effectiveness of nonsurgical treatments for CsA-induced GO, and comprehensive pre and posttransplant oral care is recommended. Further studies are needed to determine the biological mechanisms and influence of each variable on the efficacy of nonsurgical treatments in reducing drug-induced GO.